128781-28-2

Upstream product

• 94903-80-7 [1S-[1α,2α(5Z)3α,4α]]-7-[3-Formyl-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid, methyl ester 
• 537-47-3 4-phenyl-semicarbazide 
• 104596-33-0 methyl <1α,2α(Z),3α,4α>-7-<3-formyl-7-oxabicyclo<2.2.1>hept-2-yl>-5-heptenoate 

Downstream Products

• 98299-61-7 <1α,2α(Z),3α,4α>-7-<3-<<2-<(phenylamino)carbonyl>hydrazino>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>-5-heptenoic acid 
• 128781-29-3 C₂₂H₃₁N₃O₄ 
• 98672-91-4 7-(3-((2-((phenylamino)carbonyl)hydrazino)methyl)-7-oxabicyclo-[2.2.1]hept-2-yl)-5-heptenoic acid 
• 128781-29-3 methyl <1S-<1α,2α(Z),3α,4α>>-7-<3-<<2-<(phenylamino)carbonyl>hydrazino>methyl>-7-oxabicyclo<2.2.1>hept-2-yl>-5-heptenoate 

Relevant academic research and scientific papers

7-Oxabicycloheptyl Carboxylic Acids as Thromboxane A2 Antagonists: Aza ω-Chain Analogues

A novel bicyclic prostaglandin analogue, >-7-acetyl>amino>methyl>-7-oxabicyclohept-2-yl>-5-heptenoic acid ((-)-7) was found to be a potent and selective thromboxane A2 (TxA2) receptor antagonist.Unlike the related series of ω-chain allylic alcohols, amide 7 and its congeners were uniformly free of direct contractile activity in vitro (bovine coronary) and in vivo (anesthetized guinea pig).Amide 7 was effective in the inhibition of (a) arachidonic acid induced platelet aggregation of human platelet-richplasma (I50 = 0.18 +/- 0.006 μM), (b) 11,9-epoxymethano-PGH2 induced platelet aggregation of human platelet-rich plasma (I50 = 0.24 μM), (c) 11,9-epoxymethano-PGH2 induced contraction of guinea pig trachea (Kb = 3.0 +/- 0.3 nM) or rat aorta (Kb = 8.8 +/- 1.1 nM), and (d) arachidonic acid induced bronchoconstriction in the anesthetized guinea pig (0.1-1.0 mg/kg iv).Amide 7 inhibited the binding of ->-7-hydrazino>methyl>-7-oxabicyclohept-2-yl>-5-heptenoic acid to human platelet membranes in a specific and saturable manner with a Kd = 49.6 +/- 1.4 nM.